ASH 2024: Impact of Darzalex Faspro-based regimens on show

Johnson & Johnson has announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates and progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM), regardless of transplant status.

These findings were demonstrated in an expanded MRD analysis of the Phase III CEPHEUS study and a post-hoc analysis of clinically relevant subgroups in the Phase III AURIGA study, which were both featured as oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting.

The CEPHEUS study analysis demonstrated that 85% of patients who achieved MRD negativity with Darzalex Faspro were progression-free at 4.5 years.